E!115458, ALPHA, Alpha Therapy Solutions

Important results from the project

The purpose and goal of Project ALPHA was to develop a new drug for the treatment of metastatic prostate cancer (mPC), 211At-PSMA, and to evaluate it up until a completed Phase 1 study. The project also intended to develop a production platform (ATLAS) for the manufacture of 211At-PSMA and other 211At drug products. The ATLAS system was further developed in the project and launched as the commercial product, C100, in 2024. Part of the manufacturing process of 211At-PSMA can be carried out using this product. The development of 211At-PSMA is in the pre-clinical phase and is thus delayed.

Expected long term effects

The launch of the C100 module has had a big impact on Atley and our customers. The first four orders for the product have generated revenue for the company, and the delivered units will mean that Atley´s customers can more quickly commercialize new pharmaceuticals for metastatic cancer. The C100 module plays a significant role in the production of 211At-PSMA, and will be valuable in the upcoming drug development phases. The project results are expected to lead to a future commercialization of 211At-PSMA, which should lead to improved treatment options for patients with mPC.

Approach and implementation

The collaboration between Telix and Atley has generally worked very well. Monthly digital project meetings were supplemented with physical meetings to drive the project forward. When the project encountered obstacles or delays, the consortium was able to find effective solutions that were able to partially limit negative consequences. Both parties intend to continue the collaboration focused on 211At-PSMA, and also to start new collaborations focused on drugs for other cancer diagnoses.